3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
6
Neoplasms
3
Neoplasm Metastasis
3
Recurrence
2
Melanoma
2
Lymphoma, B-Cell, Marginal Zone
2
Head and Neck Neoplasms
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Nephrotic Syndrome
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Locally Advanced Bladder Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Diseases
1
Hepatitis B
1
Gastrointestinal Diseases
1
Familial Mediterranean Fever
1
Esophageal Neoplasms
1
Depression
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Arthritis, Rheumatoid
1
Anxiety Disorders
1
Interventions
Pharmaceutical Preparations
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
All Solid Tumors
×
Pharmaceutical Preparations
×
Clear all
NCT01711398
2015-02-12
IP N02
Elro Pharma
Phase 1/2
Completed
15 enrolled